New FDA approvals of adalimumab biosimilars are bringing more choice to prescribers, with high-dose concentrations and auto-injector formulations soon to be available.
This week, the FDA approved adalimumab-aaty (Yuflyma, Celltrion USA), a high-concentration (100 mg/mL) and citrate-free biosimilar of Humira (adalimumab, AbbVie), as well as a new autoinjector option, adalimumab-adbm (Cyltezo, Boehringer Ingelheim), an interchangeable biosimilar of adalimumab.
Prescribed for treating Crohn’s